These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1143 related articles for article (PubMed ID: 25983005)

  • 1. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
    Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
    Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer.
    Naito Y; Yamada K; Imamura Y; Ishii H; Matsuo N; Tokito T; Kinoshita T; Azuma K; Hoshino T
    Med Oncol; 2018 Apr; 35(5):61. PubMed ID: 29610997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.
    Garassino MC; Torri V; Michetti G; Lo Dico M; La Verde N; Aglione S; Mancuso A; Gallerani E; Galetta D; Martelli O; Collovà E; Fatigoni S; Ghidini A; Saggia C; Bareggi C; Rossi A; Farina G; Thatcher N; Blackhall F; Lorigan P; Califano R
    Lung Cancer; 2011 Jun; 72(3):378-83. PubMed ID: 20950888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer.
    Wakuda K; Kenmotsu H; Naito T; Akamatsu H; Ono A; Shukuya T; Nakamura Y; Tsuya A; Murakami H; Takahashi T; Endo M; Nakajima T; Yamamoto N
    Am J Clin Oncol; 2015 Feb; 38(1):28-32. PubMed ID: 23388567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.
    Petrioli R; Roviello G; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Martellucci I; Bianco V; Francini E
    Clin Lung Cancer; 2015 Nov; 16(6):e229-34. PubMed ID: 26072097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose Modification of Etoposide plus Platinum in Elderly Patients with Extensive-Disease Small-Cell Lung Cancer.
    Kim H; Choi E; Heo MH; Kim JY; Park KU
    Oncology; 2022; 100(6):313-319. PubMed ID: 35390786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of small cell lung cancer patients treated with cisplatin-etoposide versus carboplatin-etoposide.
    Karam I; Jiang SY; Khaira M; Lee CW; Schellenberg D
    Am J Clin Oncol; 2015 Feb; 38(1):51-4. PubMed ID: 23563211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.
    Sodja E; Knez L; Kern I; Ovčariček T; Sadikov A; Cufer T
    Eur J Cancer; 2012 Dec; 48(18):3378-85. PubMed ID: 22795264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study.
    Lee GW; Go SI; Cho YJ; Jeong YY; Kim HC; Duk Lee J; Hwang YS; Ko GH; Lee JH; Kim DC; Yang JW; Oh S; Lee JS
    J Thorac Oncol; 2012 Mar; 7(3):528-34. PubMed ID: 22258474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of platinum agents plus etoposide for patients with small cell lung cancer with interstitial lung disease.
    Yoshida T; Yoh K; Goto K; Niho S; Umemura S; Ohmatsu H; Ohe Y
    Anticancer Res; 2013 Mar; 33(3):1175-9. PubMed ID: 23482799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Correlations between genetic variations of glutathione synthetase gene and the response to platinum-based chemotherapy and prognosis of small cell lung cancer patients].
    Feng T; Li HM; Yuan P; Yu DK; Ma F; Tan WW; Du ZL; Yang J; Huang Y; Lin DX; Xu BH; Tan W
    Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):115-120. PubMed ID: 28219206
    [No Abstract]   [Full Text] [Related]  

  • 12. Topotecan-carboplatin-etoposide combination as 1st line treatment in patients with small cell lung cancer.
    Zarogoulidis K; Mylonaki E; Kakavelas P; Zarogoulidis P; Tsiouda T; Rapti E; Lithoxopoulou H; Zarogoulidou V; Kontakiotis T;
    Lung Cancer; 2009 Nov; 66(2):226-30. PubMed ID: 19321222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
    Igawa S; Shirasawa M; Fukui T; Nishinarita N; Sone H; Ozawa T; Sugita K; Okuma Y; Kurahayashi S; Ono T; Sugimoto A; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
    Oncology; 2018; 94(4):207-214. PubMed ID: 29393275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
    Langer CJ; Albert I; Ross HJ; Kovacs P; Blakely LJ; Pajkos G; Somfay A; Zatloukal P; Kazarnowicz A; Moezi MM; Schreeder MT; Schnyder J; Ao-Baslock A; Pathak AK; Berger MS;
    Lung Cancer; 2014 Sep; 85(3):420-8. PubMed ID: 24997137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes in recurrent small-cell lung cancer after one to four chemotherapy lines: a retrospective study of 300 patients.
    Nagy-Mignotte H; Guillem P; Vignoud L; Coudurier M; Vesin A; Bonneterre V; Toffart AC; Sakhri L; Brambilla C; Brambilla E; Timsit JF; Moro-Sibilot D;
    Lung Cancer; 2012 Oct; 78(1):112-20. PubMed ID: 22795703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study.
    Spigel DR; Waterhouse DM; Lane S; Legenne P; Bhatt K
    Clin Lung Cancer; 2013 Jul; 14(4):356-63. PubMed ID: 23391616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
    Baize N; Monnet I; Greillier L; Geier M; Lena H; Janicot H; Vergnenegre A; Crequit J; Lamy R; Auliac JB; Letreut J; Le Caer H; Gervais R; Dansin E; Madroszyk A; Renault PA; Le Garff G; Falchero L; Berard H; Schott R; Saulnier P; Chouaid C;
    Lancet Oncol; 2020 Sep; 21(9):1224-1233. PubMed ID: 32888454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypo- or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer.
    Zhang J; Fan M; Liu D; Zhao KL; Wu KL; Zhao WX; Zhu ZF; Fu XL
    Radiat Oncol; 2017 Mar; 12(1):51. PubMed ID: 28283034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the Merseyside and Cheshire Cancer network.
    Sallam M; Wong H; Escriu C
    BMC Pulm Med; 2019 Nov; 19(1):195. PubMed ID: 31675940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
    Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
    Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.